Acquired MET D1228V mutation and resistance to MET inhibition in lung cancer

Amplified and/or mutated MET can act as both a primary oncogenic driver and as a promoter of tyrosine kinase inhibitor (TKI) resistance in non-small cell lung cancer (NSCLC). However, the landscape of MET-specific targeting agents remains underdeveloped and understanding of mechanisms of resistance...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Discov
Main Authors: Bahcall, Magda, Sim, Taebo, Paweletz, Cloud P., Patel, Jyoti D., Alden, Ryan S., Kuang, Yanan, Sacher, Adrian G., Kim, Nam Doo, Lydon, Christine A., Awad, Mark M., Jaklitsch, Michael T., Sholl, Lynette M., Jänne, Pasi A., Oxnard, Geoffrey R.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5140694/
https://ncbi.nlm.nih.gov/pubmed/27694386
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-0686
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados